Expectations for Wnt pathway-targeting trispecific antibody remigromig (MK-3000, formerly known as EYE103) were riding high ...

Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards ...

A study has shown that the efficacy of Eli Lilly's psoriasis therapy Taltz is improved when it is given in combination with ...

For years, medtech companies have treated the digital experience around their devices as an afterthought. A layer of software ...

Asahi Kasei's $920 million takeover of German biotech Aicuris in April has paid off with FDA approval for the herpes simplex ...

While still in the early stages of development, in vivo CAR-T therapies have generated excitement about their potential as cancer therapies, and updates from a couple of class pioneers at ASCO will ...

MSD has been rocked by a court judgment ordering it to stop manufacturing and selling its subcutaneous formulation of cancer ...

The steady stream of M&A deals in pharma this year has continued with the news that GSK has agreed to buy Canada's 35Pharma and its drug candidate for pulmonary hypertension (PH) for $950 million. The ...

AZ's $2 billion investment – at $18.36 per share – puts the UK-headquartered company in the driving seat to pair its ...

As it waits for an FDA decision on one non-opioid pain drug, Viatris has its eye on two more, via a takeover bid for Pacira ...

The personalized cancer vaccine field has reached a defining milestone. With Moderna and Merck reporting positive initial ...

Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a partnership – worth up to $8 billion – that spans ...